Site selection evidence for Phase 1-3 trials

Every site on your shortlist, with its receipts.

Ranked trial sites and investigators for your indication, each line linked to the ClinicalTrials.gov record and the PubMed paper behind it. Walk into the CRO call with the list and the reasons.

See a full sample shortlist Check my CRO's list

A real shortlist: multiple myeloma, Phase 2-3

Built from 300 completed and terminated trials in the registry, pulled 2026-11-06. Top 10 of 25 sites shown, in the registry's own trial-count order.

Multiple myeloma: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	Dana Farber Cancer Institute Boston, United States · 3 spellings merged	26 20 completed, 6 terminated	NCT03301220 NCT03601078 NCT02441686	2026-05-04	19 NCT04133636 NCT05535244 NCT07258511 NCT07284758	92
2	Hackensack University Medical Center Hackensack, United States · 13 spellings merged	24 15 completed, 9 terminated	NCT04649359 NCT03601078 NCT05561751	2026-08-25	15 NCT04133636 NCT06208150 NCT04181827 NCT06356571	90
3	Medical College of Wisconsin Milwaukee, United States · 13 spellings merged	24 17 completed, 7 terminated	NCT03651128 NCT03601078 NCT03159702	2026-04-13	18 NCT07009899 NCT06208150 NCT04923893 NCT04181827	92
4	Emory University Atlanta, United States · 18 spellings merged	22 16 completed, 6 terminated	NCT04649359 NCT03301220 NCT03601078	2026-08-25	29 NCT07222761 NCT04133636 NCT07266441 NCT05438043	83
5	Memorial Sloan Kettering Cancer Center New York, United States · 14 spellings merged	22 17 completed, 5 terminated	NCT04649359 NCT05014412 NCT05561751	2026-08-25	39 NCT03315026 NCT07222761 NCT07393282 NCT04133636	88
6	Washington University School of Medicine St Louis, United States · 12 spellings merged	22 13 completed, 9 terminated	NCT03301220 NCT03601078 NCT03732703	2026-05-04	20 NCT02253316 NCT07393282 NCT04133636 NCT05438043	90
7	Mayo Clinic in Rochester Rochester, United States · 7 spellings merged	21 16 completed, 5 terminated	NCT03301220 NCT05288062 NCT03941860	2026-05-04	30 NCT02253316 NCT07393282 NCT04133636 NCT05535244	90
8	Alexandra General Hospital of Athens Athens, Greece · 17 spellings merged	21 16 completed, 5 terminated	NCT04824794 NCT03180736 NCT03215030	2025-07-31	18 NCT07455851 NCT07665450 NCT06208150 NCT07589634	82
9	CHU Nantes Nantes, France · 29 spellings merged	20 16 completed, 4 terminated	NCT03993912 NCT04649359 NCT03301220	2026-08-28	30 NCT05572515 NCT07665450 NCT04133636 NCT05438043	83
10	MD Anderson Cancer Center Houston, United States · 13 spellings merged	19 12 completed, 7 terminated	NCT03901963 NCT03652064 NCT03601078	2026-05-04	25 NCT05828511 NCT05730036 NCT07266441 NCT05455320	90

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

All 25 sites, the 10 investigators and their papers

What every row carries

The trials behind itEach site lists the comparable trials it ran, as ClinicalTrials.gov links, with the stop reason on the record for terminated studies.
The investigators and their papersPrincipal investigators and study chairs, matched to PubMed papers with a stated match confidence.
What else is recruiting thereCompeting trials in your indication at the same site, by NCT number, so you see the load before the call.
One site, one rowSpelling variants of the same facility are merged, so the trial count is the site's real count.

The CRO sent a list. See what the registry says about every name on it.

Leave your indication and, if you have it, the CRO's site list. We reply by email with what the registry says about each name on it and the strong sites it leaves out.

20 indications, ready to read

Oncology, immunology, neurology, respiratory and more. Each one is built the same way and cited the same way.

All 20 sample shortlists · The method and its tests